ArticleJournal of photochemistry and photobiology2021
Rapid inactivation of SARS-CoV-2 with LED irradiation of visible spectrum wavelengths.
Article in Journal of photochemistry and photobiology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed.
- Multispectral Antimicrobial Blue Light (aBL) Systems for Continuous Decontamination of Food-Contact Surfaces and Environmental Matrices.Foods (Basel, Switzerland) · 2026Article
- Photodynamic inactivation of Mycobacterium tuberculosis by broad-spectrum visible light.Applied microbiology and biotechnology · 2026Article
- Article
- Analysis of the SARS-CoV-2 inactivation mechanism using violet-blue light (405 nm).Applied and environmental microbiology · 2025Article
- Inactivation characteristics of a 280 nm Deep-UV irradiation dose on aerosolized SARS-CoV-2.Environment international · 2023Article
- The inhibitory and inactivating effects of visible light on SARS-CoV-2: A narrative update.Journal of photochemistry and photobiology · 2023Article
- The Wavelength-Based Inactivation Effects of a Light-Emitting Diode Module on Indoor Microorganisms.International journal of environmental research and public health · 2022Article
- SARS-CoV-2 inactivation by ultraviolet radiation and visible light is dependent on wavelength and sample matrix.Journal of photochemistry and photobiology. B, Biology · 2022Article
- Blue Laser Light Counteracts HSV-1 in the SH-SY5Y Neuronal Cell Model of Infection.Life (Basel, Switzerland) · 2022Article
- Principles and practice for SARS-CoV-2 decontamination of N95 masks with UV-C.Biophysical journal · 2021Review
- UVC disinfects SARS-CoV-2 by induction of viral genome damage without apparent effects on viral morphology and proteins.Scientific reports · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
20 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Difficulty in controlling SARS-CoV-2 transmission made the ability to inactivate viruses in aerosols and fomites to be an important and attractive risk reduction measure. Evidence that light frequencies have the ability to inhibit microorganisms has already been reported by many studies which, however, focused on ultraviolet (UV) wavelengths, which are known to induce potential injury in humans. In the present study, the effect on suspensions of SARS-CoV-2 of a Light Emitting Diode (LED) device capable of radiating frequencies in the non-hazardous visible light spectrum (VIS) was investigated. In order to evaluate the efficiency of viral inactivation, plaque assay and western blot of viral proteins were performed. The observed results showed a significant reduction in infectious particles that had been exposed to the LED irradiation of visible light. Furthermore, the analysis of the intracellular expression of viral proteins confirmed the inactivating effect of this irradiation technology. This
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.